<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1106233782
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NUCALA 100 mg POWDER FOR SOLUTION FOR INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MEPOLIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4284.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXO SMITHKLINE MANUFACTURING S.P.A." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXO SMITHKLINE MANUFACTURING S.P.A.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AC06 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>NUCALA contains the active substance<strong> mepolizumab,</strong> a <em>monoclonal antibody</em>, a type of protein designed to recognise a specific target substance in the body. It is used to treat severe asthma in adults, adolescents and children 6 years of age and over. It is also used to treat EGPA (Eosinophilic Granulomatosis with Polyangiitis) in adult patients.</p><p>&nbsp;</p><p>Mepolizumab, the active substance in NUCALA lowers the number of eosinophils (a type of white blood cell) in the bloodstream, lungs and tissues.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in"><strong><u>Severe Eosinophilic Asthma</u></strong></p><p>&nbsp;</p><p>Some people with severe asthma have too many <em>eosinophils</em> in the blood and lungs. This condition is called <em>eosinophilic asthma &ndash; </em>the type of asthma NUCALA can treat.</p><p>&nbsp;</p><p>NUCALA can reduce your number of asthma attacks, if you are already using medicines such as high dose inhalers, but your asthma is not well controlled by these medicines.</p><p>If you are taking medicines called <em>oral corticosteroids,</em> NUCALA can also help reduce the daily dose you need to control your asthma.</p><p><strong>&nbsp;</strong></p><p>Mepolizumab, the active substance in NUCALA, blocks a protein called <em>interleukin-5</em>. By blocking the action of this protein<em>, </em>it limits the production of more eosinophils from the bone marrow and lowers the number of eosinophils in the bloodstream and the lungs.</p><p><strong><em>&nbsp;</em></strong></p><p style="margin-left:0in; margin-right:0in"><strong><u>EGPA (Eosinophilic Granulomatosis with Polyangiitis)</u></strong></p><p>&nbsp;</p><p>EGPA is a condition where people have too many eosinophils in the blood and tissues and also have inflammation of the blood vessels (vasculitis). EGPA most commonly affects the lungs and sinuses but often affects other organs including the skin, heart, kidneys, nerves or bowels.</p><p>NUCALA can reduce number of eosinophils in the blood and can reduce symptoms and delay a flare-up of these symptoms in people who are already taking corticosteroids.</p><p>NUCALA can also help reduce the daily dose of corticosteroids you need to control your symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in; margin-right:0in"><strong>You must not receive NUCALA</strong></p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> to mepolizumab or any of the other ingredients of this medicine (listed in section 6).</p><p style="margin-left:46.35pt; margin-right:0in; text-indent:-.25in"><strong>Check with your doctor </strong>if you think this applies to you.</p><p style="margin-left:0in; margin-right:0in"><strong>Take special care</strong><strong> with NUCALA</strong></p><p>&nbsp;</p><p><u>Worsening Asthma</u></p><p>Some people get asthma-related side effects, or their asthma may become worse, during treatment with NUCALA.</p><p style="margin-left:46.35pt; margin-right:0in; text-indent:-.25in"><strong>Tell your doctor or nurse</strong> if your asthma remains uncontrolled, or gets worse, after you start NUCALA treatment.</p><p style="text-indent:.5in">&nbsp;</p><p><u>Allergic and injection site reactions</u></p><p>Medicines of this type <em>(monoclonal antibodies)</em> can cause severe allergic reactions when injected into the body.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p style="margin-left:46.35pt; margin-right:0in; text-indent:-.25in"><strong>Tell your doctor before you are given NUCALA</strong>, if you may have had a similar reaction to any injection or medicine.</p><p>&nbsp;</p><p><u>Parasitic infections</u></p><p>NUCALA may weaken your resistance to infections caused by parasites. If you have a parasitic infection, it should be treated before you start treatment with NUCALA.</p><p>If you live in a region where these infections are common or if you are travelling to such a region:</p><p style="margin-left:46.35pt; margin-right:0in; text-indent:-.25in"><strong>Check with your doctor </strong>if you think any of these may apply to you.</p><p>&nbsp;</p><p><strong>Children </strong></p><p>This medicine is not intended for use in <strong>children below the a</strong>ge of 6 years for the treatment of severe asthma or EGPA.</p><p><strong>Other medicines and NUCALA</strong></p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-.1pt"><strong>Tell your doctor</strong> if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in"><strong>Other medicines for asthma or EGPA</strong></p><p><!--[if !supportLists]-->&ucirc; <!--[endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Don&rsquo;t suddenly stop taking </strong>your preventer medicines for your asthma or EGPA once you have started NUCALA. These medicines (especially ones called <em>corticosteriods</em>) must be stopped gradually, under the direct supervision of your doctor and dependant on your response to NUCALA.</p><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>If you are pregnant, if you think you may be pregnant or are planning to have a baby, <strong>ask your doctor for advice</strong> before using this medicine.<strong> </strong></p><p>&nbsp;</p><p>It is not known<strong> </strong>whether the ingredients of NUCALA can pass into breast milk. <strong>If you are breast‑feeding, you must check with your doctor</strong> before you use NUCALA.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>The possible side effects of NUCALA are unlikely to affect your ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Powder for solution for injection<em><u> </u></em></strong>(powder in a vial that will be dissolved and injected by your doctor or nurse).</p><p>&nbsp;</p><p>NUCALA is given to you by a doctor, nurse or healthcare professional, as an injection just under the skin (subcutaneously).&nbsp;</p><p style="margin-left:0in; margin-right:-.1pt"><strong>&nbsp;</strong></p><p><strong><u>Severe asthma</u></strong></p><p><strong>&nbsp;</strong></p><p><strong>Adults and adolescents aged 12 years and over</strong></p><p><strong>&nbsp;</strong></p><p>The recommended dose for adults and adolescents aged 12 years and over is 100&nbsp;mg. You will be given 1 injection once every four weeks.</p><p>&nbsp;</p><p><strong>Children aged 6 to 11 years of age</strong></p><p><strong>&nbsp;</strong></p><p><strong>Children weighing &ge; 40&nbsp;kg</strong></p><p>The recommended dose is 100&nbsp;mg. You will be given 1 injection once every four weeks.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Children weighing &lt; 40&nbsp;kg</strong></p><p>&nbsp;</p><p>The recommended dose is 40&nbsp;mg. You will be given 1 injection once every four weeks.</p><p>&nbsp;</p><p><strong><u>EGPA</u></strong></p><p><strong><em>&nbsp;</em></strong></p><p>The recommended dose for adults and adolescents aged 12 years and over is 300&nbsp;mg. You will be given 3 injections once every four weeks.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>If a dose of NUCALA is missed</strong></p><p><strong>&nbsp;</strong></p><p>Contact your doctor or hospital as soon as possible to re-schedule your appointment.</p><p style="margin-left:0in; margin-right:-.1pt"><strong>&nbsp;</strong></p><p><strong>Don&rsquo;t stop NUCALA without advice</strong></p><p><strong>&nbsp;</strong></p><p>Do not stop injections of NUCALA unless your doctor advises you to. Interrupting or stopping the treatment with NUCALA may cause your symptoms to come back.</p><p style="margin-left:28.35pt; margin-right:0in">&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in">&egrave;If your symptoms get worse while receiving injections of NUCALA &nbsp;</p><p style="margin-left:46.35pt; margin-right:0in; text-indent:-.25in">Call your doctor.</p><p style="margin-left:28.35pt; margin-right:0in">&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p style="margin-left:28.35pt; margin-right:-.1pt; text-indent:-28.35pt"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects caused by NUCALA are usually mild to moderate but can occasionally be serious.</p><p>&nbsp;</p><p><u>Allergic reactions</u></p><p>&nbsp;</p><p>Allergic reactions to NUCALA are rare (they may affect up to 1 in 1000 people).</p><p>If you have any of the following symptoms after taking NUCALA:</p><p style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->skin rash (hives) or redness</p><p style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling, sometimes of the face or mouth (angioedema)</p><p style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->becoming very wheezy, coughing or having difficulty in breathing</p><p style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->suddenly feeling weak or light headed (may lead to collapse or loss of consciousness)</p><p>&egrave; &nbsp;&nbsp;&nbsp;&nbsp; Stop using NUCALA and seek medical help immediately</p><p style="margin-left:46.35pt; margin-right:0in">&nbsp;</p><p><strong>Very common side effects</strong></p><p>These may affect <strong>more than 1 in 10</strong> people:</p><p style="margin-left:.5in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->headache</p><p><strong>&nbsp;</strong></p><p><strong>Common side effects</strong></p><p>These may affect <strong>up to 1 in 10 </strong>people:</p><p style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->chest infection- symptoms of which may include cough and fever (high temperature)</p><p style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->urinary tract infection (blood in urine, painful and frequent urination, fever, pain in lower back)</p><p style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->upper abdominal pain (stomach pain or discomfort in the upper area of the stomach)</p><p style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->fever (high temperature)</p><p style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->eczema (itchy red patches on the skin)</p><p style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->injection-site reaction (pain, redness, swelling, itching, and burning sensation of the skin near where the injection was given)</p><p style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->back pain</p><p style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->pharyngitis (sore throat)</p><p style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->nasal congestion (stuffy nose)</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Rare side effects</strong></p><p>These may affect up to 1 in 1,000 people:</p><p>allergic reactions (See earlier in Section 4).</p><p><strong>&nbsp;</strong></p><p>&egrave; <strong>Tell your doctor or pharmacist </strong>if any of the side effects listed becomes <strong>severe or troublesome</strong>, or if you notice any side effects not listed in this leaflet.</p><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li><strong>Keep out of the sight and reach of children. </strong></li><li>Do not take NUCALA after the expiry date shown on the pack.</li><li>Store at between 2&deg;C and 8&deg;C.</li></ul><p style="margin-left:.5in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not freeze.</p><p style="margin-left:.5in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Store in the original package to protect from light.</p><ul><li>If your doctor tells you to stop taking NUCALA, it is important to return any remnants which are left over to your pharmacist.</li><li>Don&rsquo;t throw away any medicines in wastewater or household waste.&nbsp; Ask your pharmacist how to throw away medicines no longer required.&nbsp; This will help to protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in; margin-right:-.1pt"><strong>What NUCALA contains</strong></p><p style="margin-left:0in; margin-right:-.1pt"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:-.1pt">The active substance is mepolizumab. Each vial contains 100 mg of mepolizumab.</p><p style="margin-left:0in; margin-right:-.1pt">After reconstitution, each ml of solution contains 100&nbsp;mg mepolizumab.</p><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p><p style="margin-left:0in; margin-right:-.1pt">The other ingredients are sucrose, sodium phosphate dibasic heptahydrate and polysorbate 80.</p><p style="margin-left:0in; margin-right:-.1pt"><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What NUCALA looks like and contents of the pack
	
	NUCALA is a lyophilised white powder supplied in a clear, colourless glass vial with a rubber stopper.
	
	NUCALA is available in a pack containing 1 single use vial or in multipacks with 3 individual single use vials.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in; margin-right:0in"><strong>7. Information for healthcare professionals</strong></p><p><strong>&nbsp;</strong></p><p><strong>Step-by-step instructions for use and handling, reconstitution, and administration</strong></p><p><strong>&nbsp;</strong></p><p>NUCALA is provided as a lyophilised, white powder in a single-use vial for subcutaneous injection only. NUCALA does not contain a preservative therefore reconstitution should be carried out under aseptic conditions.</p><p>Once reconstituted, NUCALA will contain a concentration of 100&nbsp;mg/mL mepolizumab. The solution for injection can be stored between 2&deg;C to 30&deg;C for no more than 8&nbsp;hours. Any unused concentrate or solution remaining after 8&nbsp;hours must be discarded.</p><p>&nbsp;</p><p><u>Instructions for reconstitution for each vial</u></p><p><u>&nbsp;</u></p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Reconstitute the contents of the vial with 1.2&nbsp;mL of sterile water for injection </strong>preferably using a 2 to 3&nbsp;ml syringe and a 21 gauge needle. The stream of sterile water should be directed vertically, onto the centre of the lyophilised cake. Allow the vial to sit at room temperature during reconstitution, gently swirling the vial for 10 seconds with circular motion at 15-second intervals until the powder is dissolved.</p><p>&nbsp;</p><p><em>Note: The reconstituted solution <strong>must not be shaken</strong> during the procedure as this may lead to product foaming or precipitation. Reconstitution is typically complete within 5 minutes after the sterile water has been added, but it may take additional time. </em></p><p>&nbsp;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If a mechanical reconstitution device (swirler) is used to reconstitute NUCALA, reconstitution can be accomplished by swirling at 450&nbsp;rpm for no longer than 10&nbsp;minutes. Alternatively, swirling at 1000&nbsp;rpm for no longer than 5&nbsp;minutes is acceptable.</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Following reconstitution, NUCALA should be visually inspected for particulate matter and clarity prior to use.&nbsp; The solution should be clear to opalescent, and colourless to pale yellow or pale brown, free of visible particles. Small air bubbles, however, are expected and acceptable. If particulate matter remains in the solution or if the solution appears cloudy or milky, the solution must be not used.</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The reconstituted solution, if not used immediately must be:</p><p style="margin-left:.75in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Protected from sunlight</p><p style="margin-left:.75in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Stored below 30&deg;C, not frozen</p><p style="margin-left:.75in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Discarded if not used within 8 hours of reconstitution</p><p><u>&nbsp;</u></p><p><u>Instructions for administration of each </u>100&nbsp;mg<u> dose</u></p><p><u>&nbsp;</u></p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->For subcutaneous administration a 1&nbsp;mL polypropylene syringe fitted with a disposable needle 21 gauge to 27 gauge x 0.5 inch (13 mm) should preferably be used.</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Just prior to administration, remove 1&nbsp;mL of reconstituted NUCALA from one vial.&nbsp; Do not shake the reconstituted solution during the procedure as this could lead to product foaming or precipitation.</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Administer the 1&nbsp;mL injection (equivalent to 100&nbsp;mg mepolizumab) subcutaneously into the upper arm, thigh, or abdomen.</p><p>&nbsp;</p><p><strong><em>If more than one vial is required for administration of the prescribed dosage, repeat steps 1 to 3. It is recommended that individual injection sites are separated by at least 5 cm.</em></strong></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Disposal</u></p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in"><strong>Manufactured by:</strong></p><p>GlaxoSmithKline Manufacturing S.p.A*, Parma, Italy</p><p style="margin-left:0in; margin-right:0in"><strong>Marketing Authorisation Holder:</strong></p><p>Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia.</p><p>*member of the GlaxoSmithKline group of companies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                NUCALA is a trademark owned by or licensed to the GSK group of companies.
© 2019 GSK group of companies. All Rights Reserved.

GDS Version Number:  12
GDS Version Date:  25 June 2019

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي نوكالا على المادة الفعَّالة <strong>&nbsp;میپولیزوماب، </strong>وهي <em>جسم مضاد أحادي النسيلة</em> يعتبر نوعًا من البروتين المصمم للتعرف على مادة مستهدفة محددة في الجسم. ويستخدَم الدواء لعلاج الربو الحاد لدى البالغين والمراهقين والأطفال الذين تبلغ أعمارهم 6 أعوام فما فوق. كما أنه يستخدم لعلاج متلازمة شيرج ستروس مع التهاب الأوعية (EGPA) في المرضى البالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المادة الفعَّالة في نوكالا، <strong>میپولیزوماب</strong>، تقلل من عدد الحمضات (نوع من خلايا الدم البيضاء) في مجرى الدم والرئتين والأنسجة.</p><p dir="RTL" style="margin-left:0in; margin-right:0in"><strong><u>الربو اليوزيني الحاد</u></strong></p><p dir="RTL">بعض المصابين بالربو الوخيم يكون لديهم الكثير من <em>الحمضات</em> في الدم والرئتين. ويُطلق على هذه الحالة <em>الربو اليوزيني</em> - نوع الربو الذي يمكن علاجه باستخدام دواء نوكالا.</p><p dir="RTL">يمكن أن يقلل نوكالا من عدد نوبات الربو، إذا كنت تستخدم بالفعل أدوية مثل أجهزة الاستنشاق ذات الجرعات العالية، ولكن هذه الأدوية لا تسيطر بشكل جيد على الربو.</p><p dir="RTL">إذا كنت تتناول أدوية يُطلَق عليها <em>الكورتيكوستيرويدات&rlm;</em>‫<em> الفموية</em>، فيمكن أن يساعد نوكالا أيضًا في تقليل الجرعة اليومية التي تحتاجها للسيطرة على الربو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعمل <strong>میپولیزوماب</strong>، المادة الفعَّالة في نوكالا، على حجب بروتين يُطلَق عليه <em>إنترلوكين-5</em>. وعن طريق حجب عمل هذا البروتين،<em> </em>فإنه يحد من إنتاج المزيد من الحمضات من نخاع العظام ويقلل من عدد الحمضات في مجرى الدم والرئتين.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in"><strong><u>متلازمة شيرج ستروس (</u></strong><strong><u>EGPA</u></strong><strong><u>)</u></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">متلازمة شيرج ستروس هي حالة يكون فيها لدى الأشخاص الكثير من الحمضات في الدم والأنسجة وأيضًا التهاب في الأوعية الدموية (&rlm;‫الالتهاب الوعائي). وتؤثر متلازمة شيرج ستروس بشكل أكثر شيوعًا على الرئتين والجيوب الأنفية ولكنها غالبًا ما تؤثر على أعضاء أخرى، منها الجلد أو القلب أو الكليتين أو الأعصاب أو الأمعاء.</p><p dir="RTL">يمكن أن يقلل نوكالا من عدد الحمضات في الدم ويمكن أن يقلل من الأعراض ويؤخر ظهور هذه الأعراض لدى الأشخاص الذين يتناولون الكورتيكوستيرويدات&rlm;‫ بالفعل.</p><p dir="RTL">يمكن أن يساعد نوكالا أيضًا في تقليل الجرعة اليومية التي تحتاجها من الكورتيكوستيرويدات&rlm;‫ للسيطرة على الأعراض.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:0in; margin-right:0in"><strong>يجب عدم تلقي العلاج بدواء نوكالا</strong></p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك <strong>حساسية </strong>&nbsp;<strong>لمیپولیزوماب</strong> أو من أي من المكوِّنات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL" style="margin-left:0in; margin-right:46.35pt; text-indent:-.25in"><strong>تحدث إلى طبيبك </strong>إذا كنت تعتقد أن هذا الأمر ينطبق عليك.</p><p dir="RTL" style="margin-left:0in; margin-right:0in"><strong>ينبغي توخي الحذر بشكل خاص</strong><strong> عند استعمال نوكالا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تفاقم الربو</u></p><p dir="RTL">يصاب بعض الأشخاص بآثار جانبية مرتبطة بالربو، أو قد تسوء حالة الربو أثناء العلاج باستخدام نوكالا.</p><p dir="RTL" style="margin-left:0in; margin-right:46.35pt; text-indent:-.25in"><strong>أخبر طبيبك أو الممرضة</strong> إذا ظلت حالة الربو خارج السيطرة، أو إذا ازدادت سوءًا، بعد بدء العلاج بنوكالا.</p><p dir="RTL" style="text-indent:.5in">&nbsp;</p><p dir="RTL"><u>الحساسية والتفاعلات في موضع الحَقن</u></p><p dir="RTL">يمكن أن تسبب الأدوية من هذا النوع <em>(الأجسام المضادة وحيدة النسيلة)</em> تفاعلات حساسية شديدة عند حقنها في الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:46.35pt; text-indent:-.25in"><strong>أخبر طبيبك قبل أن يتم إعطاؤك نوكالا</strong>، إذا كنت قد تعرضت لتفاعل مماثل من أي حقن أو دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>العدوى الطفيلية</u></p><p dir="RTL">قد يُضعِف نوكالا مقاومتك للعدوى التي تسببها الطفيليات. إذا كنت مصابًا بعدوى طفيلية، فيجب علاجها قبل بدء العلاج باستخدام نوكالا.</p><p dir="RTL">إذا كنت تعيش في منطقة تنتشر فيها هذه العدوى أو إذا كنت مسافرًا إلى منطقة من هذه المناطق:</p><p dir="RTL" style="margin-left:0in; margin-right:46.35pt; text-indent:-.25in"><strong>استشر طبيبك </strong>إذا كنت ترى أن أي من هذه الأمور قد تنطبق عليك<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال </strong></p><p dir="RTL">هذا الدواء غير مخصص للاستخدام مع <strong>الأطفال دون عمر</strong> 6 أعوام لعلاج الربو الحاد أو متلازمة شيرج ستروس.</p><p dir="RTL"><strong>الأدوية الأخرى ونوكالا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL" style="margin-left:-.1pt; margin-right:0in"><strong>أخبر طبيبك</strong> إذا كنت تتناول أي أدوية أخرى أو تناولت أي أدوية أخرى مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt"><strong>الأدوية الأخرى المُستخدَمة لعلاج الربو أو متلازمة شيرج ستروس</strong></p><p dir="RTL"><!--[if !supportLists]-->&ucirc;&nbsp;&nbsp; <!--[endif]--><strong>لا تتوقف فجأة عن تناول </strong>أدوية الوقاية الخاصة بعلاج الربو أو متلازمة شيرج ستروس بمجرد بدء استخدام نوكالا. يجب إيقاف هذه الأدوية (خاصة تلك التي تسمى <em>الكورتيكوستيرويدات</em>) بشكل تدريجي، تحت إشراف مباشر من طبيبك ووفقًا لاستجابتك لدواء نوكالا.</p><p dir="RTL" style="margin-left:-.1pt; margin-right:0in">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملاً أو تظنين أنكِ حامل أو تنوين الحمل، <strong>يجب استشارة طبيبك</strong> قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف ما إذا كان من الممكن انتقال مكوِّنات<strong> </strong>نوكالا إلى لبن الأم.<strong> وإذا كنتِ ترضعين رضاعة طبيعية، فينبغي استشارة طبيبك</strong> قبل استخدام نوكالا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المرجح أن تؤثر الآثار الجانبية المحتملة لدواء نوكالا على قدرتك على القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مسحوق لمحلول الحقن<em> </em></strong>(مسحوق في قارورة يقوم طبيبك أو الممرضة بإذابته وحقنه).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء نوكالا لك بواسطة طبيب أو ممرضة أو اختصاصي رعاية صحية، بالحقن تحت الجلد مباشرةً.</p><p dir="RTL" style="margin-left:-.1pt; margin-right:0in">&nbsp;</p><p dir="RTL"><strong><u>الربو الحاد</u></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون والمراهقون البالغون 12 عامًا وأكثر</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها للبالغين والمراهقين الذين تتراوح أعمارهم بين 12 عامًا وأكثر هي 100 ملجم. سيتم إعطاؤك حقنة واحدة مرة واحدة كل أربعة أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال الذين تتراوح أعمارهم بين 6 إلى 11 عامًا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال الذين يزنون 40 كلجم أو أكثر</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">الجرعة الموصى بها عي 100 ملجم. سيتم إعطاؤك حقنة واحدة مرة واحدة كل أربعة أسابيع.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال الذين يزنون أقل من 40 كلجم </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">الجرعة الموصى بها هي 40 ملجم. سيتم إعطاؤك حقنة واحدة مرة واحدة كل أربعة أسابيع.</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>متلازمة شيرج ستروس</u></strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">الجرعة الموصى بها للبالغين والمراهقين الذين تتراوح أعمارهم بين 12 عامًا وأكثر هي 300 ملجم. سيتم إعطاؤك 3 حُقَن مرة واحدة كل أربعة أسابيع.</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong>في حالة تفويت جرعة نوكالا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك أو اذهب إلى المستشفى في أقرب وقت ممكن لتحديد موعد آخر.</p><p dir="RTL" style="margin-left:-.1pt; margin-right:0in">&nbsp;</p><p dir="RTL"><strong>لا توقف العلاج بنوكالا دون استشارة المختص</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتوقف عن حقن نوكالا ما لم ينصحك طبيبك بذلك. فإن قطع العلاج بنوكالا أو وقفه قد يتسبب في ظهور الأعراض مرة أخرى.</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt">&ccedil;إذا ازدادت الأعراض سوءًا أثناء تلقي العلاج بحقن نوكالا</p><p dir="RTL" style="margin-left:0in; margin-right:46.35pt; text-indent:-.25in">اتصل بطبيبك.</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول تناول هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يتسبب هذا الدواء في حدوث أعراض جانبية، ولكن ليس بالضرورة أن يصاب بها جميع الأشخاص. عادةً ما تكون الآثار الجانبية الناتجة عن نوكالا خفيفة إلى متوسطة، ولكن يمكن أن تكون خطيرة في بعض الأحيان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تفاعلات الحساسية</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&rlm;‫تفاعلات الحساسية لنوكالا نادرة (قد تصيب حتى شخص واحد بين كل 1000 شخص).</p><p dir="RTL">إذا ظهرت لديك أي من الأعراض التالية بعد استخدام نوكالا:</p><p dir="RTL" style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->طفح جلدي (شرى) أو احمرار</p><p dir="RTL" style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->تورم، أحيانًا في الوجه أو الفم (وذمة وعائية)</p><p dir="RTL" style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->&rlm;‫أزيز صدري شديد أثناء التنفس أو سعال أو وجود صعوبة في التنفس</p><p dir="RTL" style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->شعور مفاجئ بالضعف والدوخة (قد يؤدي إلى الإغماء أو فقدان الوعي)</p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp;&nbsp; توقف عن استخدام نوكالا واطلب المساعدة الطبية فورًا</p><p dir="RTL" style="margin-left:0in; margin-right:46.35pt">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدًا</strong></p><p dir="RTL">يمكن أن تصيب هذه الآثار <strong>أكثر من شخص واحد بين كل 10</strong> أشخاص:</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->صداع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong></p><p dir="RTL">يمكن أن تصيب هذه الآثار <strong>حتى شخص واحد بين كل 10 </strong>أشخاص:</p><p dir="RTL" style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الالتهابات الصدرية - قد تشمل الأعراض السعال والحمى (ارتفاع في درجة الحرارة)</p><p dir="RTL" style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التهاب المسالك البولية (دم في البول، تبول مؤلم ومتكرر، حمى، ألم أسفل الظهر)</p><p dir="RTL" style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم أعلى البطن (ألم في المعدة أو مغص في الجزء العلوي من المعدة)</p><p dir="RTL" style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الحمى (ارتفاع درجة الحرارة)</p><p dir="RTL" style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الإكزيما (بقع حمراء مثيرة للحكة على الجلد)</p><p dir="RTL" style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تفاعل في موضع الحقن (ألم واحمرار وتورم وحكة وحرقان في الجلد بالقرب من موضع الحقن)</p><p dir="RTL" style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم في الظهر</p><p dir="RTL" style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التهاب البلعوم (التهاب الحلق)</p><p dir="RTL" style="text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->احتقان الأنف (انسداد الأنف)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة</strong></p><p dir="RTL">يمكن أن تصيب هذه الآثار شخصًا واحدًا بين كل 1000 شخص:</p><p dir="RTL">تفاعلات الحساسية (انظر القسم 4 أعلاه).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&ccedil; <strong>أخبر الطبيب أو الصيدلي </strong>في حالة <strong>تفاقم أي من الأعراض الجانبية الموضحة هنا أو إذا أصبحت مزعجة</strong>، أو إذا لاحظت أي أعراض جانبية غير مبيَّنة في هذه النشرة.</p><p dir="RTL" style="margin-left:-.1pt; margin-right:0in">&nbsp;</p><p dir="RTL" style="text-align:center">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="RTL"><strong>يجب حفظه بعيدًا عن مرأى ومتناول الأطفال. </strong></li><li dir="RTL">لا تتناول نوكالا بعد تاريخ انتهاء الصلاحية المدون على العبوة.</li><li dir="RTL">يُخزن في درجة حرارة بين 2 إلى 8 درجة مئوية.</li></ul><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا يجب تجميده.</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يُحفظ في العبوة الأصلية لحمايته من الضوء.</p><ul><li dir="RTL">إذا نصح الطبيب بضرورة التوقف عن تناول نوكالا، فمن الضروري إعادة ما تبقى منه إلى الصيدلي.</li><li dir="RTL">لا تتخلص من الأدوية في مياه الصرف الصحي ولا المخلفات المنزلية. اسأل الصيدلي عن الطريقة المناسبة للتخلص من الأدوية التي لم تعد هناك حاجة لها. فهذا من شأنه أن يساعد في الحفاظ على البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:-.1pt; margin-right:0in"><strong>محتويات نوكالا</strong></p><p dir="RTL" style="margin-left:-.1pt; margin-right:0in">&nbsp;</p><p dir="RTL" style="margin-left:-.1pt; margin-right:0in">المادة الفعَّالة بهذا الدواء هي <strong>میپولیزوماب</strong>. تحتوي كل قنينة على 100 ملجم من <strong>المیپولیزوماب</strong>.بعد مزجه، يحتوي كل 1 مل من المحلول على 100 ملجم من <strong>میپولیزوماب</strong>.</p><p dir="RTL" style="margin-left:-.1pt; margin-right:0in">&nbsp;</p><p dir="RTL" style="margin-left:-.1pt; margin-right:0in">المكونات الأخرى هي السكروز وفوسفات الصوديوم سباعي الهيدرات ثنائي القاعدة وبوليسوربات 80.</p><p dir="RTL" style="margin-left:-.1pt; margin-right:0in">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:-.1pt; margin-right:0in"><strong>شكل نوكالا ومحتويات العبوة</strong></p><p dir="RTL" style="margin-left:-.1pt; margin-right:0in">&nbsp;</p><p dir="RTL" style="margin-left:-.1pt; margin-right:0in">نوكالا هو مسحوق أبيض مجفف بالتجميد يتوفر في قنينة زجاجية عديمة اللون بسدادة من المطاط.</p><p dir="RTL" style="margin-left:-.1pt; margin-right:0in">&nbsp;</p><p dir="RTL" style="margin-left:-.1pt; margin-right:0in">يتوفر نوكالا في عبوة تحتوي على قنينة مخصصة للاستخدام لمرة واحدة أو في عبوات متعددة القنينات بها 3 قنينات كل منها مخصصة للاستخدام لمرة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:0in; margin-right:.5in; text-indent:-35.1pt"><!--[if !supportLists]--><strong>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>معلومات لاختصاصيي الرعاية الصحية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات خطوة بخطوة للاستخدام والمناولة والمزج والتناول</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر نوكالا على شكل مسحوق أبيض مجفف بالتجميد في قنينة مخصصة للاستخدام لمرة واحدة للحقن تحت الجلد فقط. لا يحتوي نوكالا على مواد حافظة، لذا يجب أن يتم المزج في أجواء معقمة.</p><p dir="RTL">بعد مزج نوكالا، سوف يكون تركيزه 100 ملجم/مل من <strong>میپولیزوماب</strong>. يمكن تخزين محلول الحقن بين درجة حرارة 2 إلى 30 لمدة لا تزيد عن 8 ساعات. يجب التخلص من أي مادة مركزة أو محلول غير مستخدم متبقي بعد 8 ساعات.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>تعليمات المزج لكل قنينة</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-indent:-.25in"><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>امزج محتويات القارورة مع 1.2 مل من الماء المعقم للحقن </strong>ويفضل باستخدام حقنة مقاس 2 إلى 3 مل وإبرة مقاس&nbsp;21. عند ضخ الماء المعقم داخل القنينة، يجب توجيهه رأسيًا إلى منتصف الكتلة المجففة بالتبريد. اترك القنينة في درجة حرارة الغرفة أثناء المزج، وحركها دائريًا برفق لمدة 10 ثوانٍ كل 15 ثانية، حتى يذوب المسحوق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>ملاحظة:</em> <strong><em>لا يجب رج</em></strong> <em>المحلول الممزوج أثناء الحقن لأن ذلك قد يؤدي إلى تكوين رغوة أو ترسب. عادةً ما يكتمل المزج خلال 5 دقاق بعد إضافة الماء المعقم، ولكنه قد يستغرق وقتًا أكثر.</em></p><p dir="RTL">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-indent:-.25in"><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في حالة استخدام جهاز مزج ميكانيكي (أداة مزج) لمزج نوكالا، يمكن أن يتم المزج بسرعة 450&nbsp;دورة بالدقيقة لمدة لا تتعدى 10&nbsp;دقائق. أو يمكن أيضًا المزج بسرعة 1000 دورة في الدقيقة لمدة لا تزيد عن 5 دقائق.</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-indent:-.25in"><!--[if !supportLists]-->3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->وبعد المزج، ينبغي فحص نوكالا ببصرك للتأكد من عدم وجود أي جسيمات والتأكد من نقاء المحلول قبل الاستخدام. يجب أن يكون المحلول رائقًا إلى غميم وعديم اللون إلى أصفر باهت أو بني باهت، خالٍ من الجزيئات المرئية. ولكن قد يتوقع وجود فقاعات هوائية صغيرة، وهذا أمر مقبول. إذا تبقت جسيمات في المحلول أو إذا ظهر المحلول غائما أو حليبيًا، فيجب عدم استخدام المحلول.</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-indent:-.25in"><!--[if !supportLists]-->4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا لم يتم استخدامه على الفور، يجب أن يكون المحلول الممزوج:</p><p dir="RTL" style="margin-left:0in; margin-right:.75in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->محميًا من أشعة الشمس</p><p dir="RTL" style="margin-left:0in; margin-right:.75in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يجب تخزينه في درجة حرارة أقل من 30 درجة مئوية، بدون تجميد</p><p dir="RTL" style="margin-left:0in; margin-right:.75in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يجب التخلص منه إذا لم يُستخدم في غضون 8 ساعات من مزجه</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تعليمات إعطاء كل جرعة 100 ملجم</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-indent:-.25in"><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->بالنسبة للإعطاء تحت الجلد، يفضل استخدام حقنة من البولي بروبيلين مقاس 1 مل مزودة بإبرة مقاس 21 مخصصة للاستخدام لمرة واحدة إلى مقاس 27 &times; 0.5 بوصة (13 مم).</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-indent:-.25in"><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->قبل الإعطاء مباشرةً، قم بأخذ 1 مل من محلول نوكالا الممزوج من قنينة واحدة. لا يجب رج المحلول الممزوج أثناء الحقن لأن ذلك قد يؤدي إلى تكوين رغوة أو ترسب.</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-indent:-.25in"><!--[if !supportLists]-->3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يتم إعطاء حقنة بسعة 1 مل (أي ما يعادل 100 ملجم <strong>میپولیزوماب</strong>) تحت الجلد في الجزء العلوي من الذراع أو الفخذ أو البطن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>إذا كانت هناك حاجة إلى أكثر من قنينة واحدة من أجل إعطاء الجرعة الموصوفة، كرر الخطوات من 1 إلى 3. يوصى بفصل مواضع الحقن المختلفة على مسافة 5 سم على الأقل.</em></strong></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>التخلص من الدواء</u></p><p dir="RTL">يجب التخلص من أي منتج دوائي غير مستخدم أو نفايات وفقًا للشروط المحلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تصنيع:</strong></p><p dir="RTL" style="margin-left:0in; margin-right:-4.95pt">جلاكسو سميث كلاين مانيوفاكتشرينج، إس بي أيه *، بارما، ايطاليا</p><p dir="RTL"><strong>الشركة المالكة لرخصة التسويق</strong></p><p dir="RTL" style="margin-left:0in; margin-right:-4.95pt">جلاكسو العربية السعودية المحدودة*، جدة، السعودية</p><p dir="RTL" style="margin-left:0in; margin-right:-4.95pt">* شركة تنتمي إلى مجموعة شركات جلاكسو سميث كلاين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوكالا علامة تجارية مملوكة أو مرخصة لمجموعة شركات جلاكسو سميث كلاين.
© 2019 جلاكسو سميث كلاين، جميع الحقوق محفوظة.
نص رقم: 12
تاريخ الإصدار: 25 يونيو 2019

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NUCALA, powder for solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 100 mg mepolizumab. After reconstitution, each ml of solution contains 100 mg mepolizumab.
Mepolizumab is a humanised monoclonal antibody (IgG1, kappa), directed against human interleukin 5 (IL 5) produced in Chinese hamster ovary cells by recombinant DNA technology.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection
Lyophilised white powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Severe Eosinophilic Asthma</strong></p><p><em>NUCALA</em> is indicated as add-on maintenance treatment of severe eosinophilic asthma in patients 6 years and older.</p><p><strong>Eosinophilic Granulomatosis with Polyangiitis (EGPA)</strong></p><p>NUCALA is indicated as add-on treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in adult patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>NUCALA</em> should be administered by a health care professional.</p><p>Following reconstitution, <em>NUCALA</em> should only be administered as a subcutaneous injection (e.g. upper arm, thigh, or abdomen) (see <em>Use and Handling</em>).</p><p><strong>Populations</strong></p><p><strong>Severe Eosinophilic Asthma</strong></p><p><strong>Adults and Adolescents (12 years and older)</strong></p><p>The recommended dose is 100 mg of<em> NUCALA</em> administered by subcutaneous (SC) injection once every 4 weeks.</p><p><strong>Children aged 6 to 11 years old:</strong></p><p><strong>Children weighing &ge; 40&nbsp;kg</strong></p><p>The recommended dose is 100&nbsp;mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks.</p><p><strong>Children weighing &lt; 40&nbsp;kg</strong></p><p>The recommended dose is 40&nbsp;mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks</p><p><strong><em>Each vial of </em></strong>NUCALA<strong><em> should be used for a single patient,</em></strong> and any remainder of the vial should be discarded.</p><p>The safety and efficacy of NUCALA have not been established in children less than 6 years of age.</p><p><strong>EGPA</strong></p><p><strong><em>It is recommended that the sites for each injection are separated by at least 5&nbsp;cm (see Use and Handling).</em></strong></p><p>The recommended dose is 300&nbsp;mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks.</p><p><strong>Elderly (65 years or older)</strong></p><p>No dosage adjustment is recommended in patients 65 years or older (see <em>Pharmacokinetics &ndash; Special Patient Populations</em>).</p><p><strong>Renal Impairment</strong></p><p>Dose adjustments in patients with renal impairment are unlikely to be required (see <em>Pharmacokinetics &ndash; Special Patient Populations</em>).</p><p><strong>&nbsp;</strong></p><p><strong>Hepatic Impairment</strong></p><p>Dose adjustments in patients with hepatic impairment are unlikely to be required (see <em>Pharmacokinetics &ndash; Special Patient Populations</em>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to mepolizumab or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>NUCALA</em> should not be used to treat acute asthma exacerbations.</p><p>Asthma-related adverse events or exacerbations may occur during treatment with <em>NUCALA.</em> Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with <em>NUCALA</em>.</p><p>Abrupt discontinuation of corticosteroids after initiation of <em>NUCALA</em> therapy is not recommended.&nbsp; Reductions in corticosteroid doses, if required, should be gradual and performed under the supervision of a physician.</p><p><strong><u>Hypersensitivity and Administration Reactions</u></strong></p><p>Acute and delayed systemic reactions, including hypersensitivity reactions (e.g. anaphylaxis, urticaria, angioedema, rash, bronchospasm, hypotension), have occurred following administration of <em>NUCALA</em>.These reactions generally occur within hours of administration, but in some instances had a delayed onset (i.e., days).</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Parasitic Infections</u></strong></p><p>Eosinophils may be involved in the immunological response to some helminth infections. Patients with pre-existing helminth infections were excluded from participation in the clinical programme. Patients with pre-existing helminth infections should be treated for their infection prior to mepolizumab therapy. If patients become infected whilst receiving treatment with mepolizumab and do not respond to anti-helminth treatment, temporary discontinuation of <em>NUCALA</em> should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No formal interaction studies have been performed with mepolizumab.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fertility</p><p>There are no fertility data in humans. Animal studies showed no adverse effects of anti-IL5 treatment on fertility (see<em> </em><em>Pre-clinical Safety Data</em>).</p><p>Pregnancy</p><p>The effect of mepolizumab on human pregnancy is unknown. No treatment related effects on embryo-foetal or postnatal development have been shown in animal studies <em>(see Pre-clinical Safety Data)</em>.</p><p><em>NUCALA</em> should be used during pregnancy only if the expected benefit to the mother justifies the potential risk to the foetus.</p><p>Lactation</p><p>There are no data regarding the excretion of mepolizumab in human milk. However, mepolizumab was excreted into the milk of cynomolgous monkeys at concentrations that were less than 0.5% of those detected in plasma.</p><p>A decision should be made whether to discontinue breast-feeding or discontinue <em>NUCALA</em>, taking into account the importance of breast-feeding to the infant and the importance of the drug to the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no studies to investigate the effect of mepolizumab on driving performance or the ability to operate machinery. A detrimental effect on such activities would not be anticipated from the pharmacology or adverse reaction profile of <em>NUCALA</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Severe asthma</p><p>The safety of <em>NUCALA</em> was studied in a clinical development program in adolescents and adults with severe eosinophilic asthma which included 3 randomised, placebo-controlled, multicentre studies (n=1327). Subjects received either subcutaneous (SC) or intravenous (IV) mepolizumab or placebo during clinical studies of 24-52 weeks duration. Adverse reactions associated with <em>NUCALA</em> 100 mg administered subcutaneously (n=263) are presented in the table below. The safety profile of NUCALA in severe asthma patients (n=998) treated for a median of 2.8 years (range 4 weeks to 4.5 years) in open-label extension studies was similar to that observed in the placebo-controlled studies. Thirty-six children (aged 6-11) with severe eosinophilic asthma received NUCALA&nbsp; for 12 weeks. After a treatment interruption of 8 weeks, 30 of these received NUCALA for a further 52 weeks. No additional adverse reactions were identified to those reported for the adolescent and adult severe asthma studies.</p><p>The frequency of adverse reactions is defined using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10) uncommon (&ge;1/1,000 to &lt;1/100) and rare (&ge;1/10000 to &lt;1/1000).</p><table cellspacing="0" cellpadding="0" border="1" style="width:573px"><thead><tr><td style="vertical-align:top; width:2.15in"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top; width:191.35pt"><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top; width:83.6pt"><p style="margin-left:-.9pt; text-indent:.9pt"><strong>Frequency</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top; width:2.15in"><p>Infections &amp; infestations</p></td><td style="vertical-align:top; width:191.35pt"><p>Lower respiratory tract infection</p><p>Urinary tract infection</p><p>Pharyngitis</p></td><td style="vertical-align:top; width:83.6pt"><p style="margin-left:-.9pt; text-indent:.9pt">Common</p><p style="margin-left:-.9pt; text-indent:.9pt">&nbsp;</p></td></tr><tr><td style="height:48.8pt; vertical-align:top; width:2.15in"><p>Immune system disorders</p></td><td style="height:48.8pt; vertical-align:top; width:191.35pt"><p>Hypersensitivity reactions (systemic allergic)*</p><p>Anaphylaxis**</p></td><td style="height:48.8pt; vertical-align:top; width:83.6pt"><p style="margin-left:-.9pt; margin-right:0in; text-indent:.9pt">Common</p><p>&nbsp;</p><p>Rare</p></td></tr><tr><td style="vertical-align:top; width:2.15in"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:191.35pt"><p>Headache</p></td><td style="vertical-align:top; width:83.6pt"><p style="margin-left:-.9pt">Very common</p></td></tr><tr><td style="vertical-align:top; width:2.15in"><p>Respiratory, thoracic &amp; mediastinal disorders</p></td><td style="vertical-align:top; width:191.35pt"><p>Nasal congestion</p></td><td style="vertical-align:top; width:83.6pt"><p style="margin-left:-.9pt; text-indent:.9pt">Common</p></td></tr><tr><td style="vertical-align:top; width:2.15in"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:191.35pt"><p>Abdominal pain upper</p></td><td style="vertical-align:top; width:83.6pt"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:2.15in"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:191.35pt"><p>Eczema</p></td><td style="vertical-align:top; width:83.6pt"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:2.15in"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:191.35pt"><p>Back pain</p></td><td style="vertical-align:top; width:83.6pt"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:2.15in"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:191.35pt"><p>Administration-related reactions (systemic non allergic)***</p><p>Local injection site reactions</p><p>Pyrexia</p></td><td style="vertical-align:top; width:83.6pt"><p style="margin-left:-.9pt; text-indent:.9pt">Common</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p style="text-align:justify">* Systemic reactions including hypersensitivity have been reported at an overall incidence comparable to that of placebo.</p><p style="text-align:justify">**From spontaneous post marketing reporting.</p><p style="text-align:justify">*** The most common manifestations associated with reports of systemic non-allergic administration-related reactions were rash, flushing and myalgia; these manifestations were reported infrequently and in &lt;1% of subjects receiving mepolizumab 100 mg subcutaneously.</p><p>EGPA</p><p>In a double-blind placebo controlled study in subjects with EGPA (NUCALA 300&nbsp;mg n= 68, placebo n= 68) no additional adverse reactions were identified to those reported for the severe asthma studies.</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222, Ext: 2317-2356-2340</li><li>Reporting hotline: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul><p><strong>&nbsp;</strong></p><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: saudi.safety@gsk.com</li><li>Website: https://gskpro.com/en-sa/</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no clinical experience with overdose of <em>NUCALA</em>.</p><p>Single doses of up to 1500&nbsp;mg of mepolizumab were administered intravenously in a clinical trial to patients with eosinophilic disease without evidence of dose-related toxicities.</p><p>Treatment</p><p>There is no specific treatment for an overdose with mepolizumab. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.</p><p>Further management should be as clinically indicated or as recommended by the national poisons centre, where available.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code</p><p>Pharmacotherapeutic group: Drugs for obstructive airway diseases, other systemic drugs for obstructive airway diseases</p><p>R03DX09</p><p>Mechanism of action</p><p>Mepolizumab is a humanised monoclonal antibody (IgG1, kappa), which targets human interleukin‑5 (IL‑5) with high affinity and specificity.&nbsp; IL‑5 is the major cytokine responsible for the growth and differentiation, recruitment, activation and survival of eosinophils.&nbsp; Mepolizumab inhibits the bioactivity of IL-5 with nanomolar potency by blocking the binding of IL‑5 to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface, thereby inhibiting IL-5 signalling and reducing the production and survival of eosinophils.</p><p><strong>Pharmacodynamic effects</strong></p><p>In clinical trials, reduction in blood eosinophils was observed consistently following treatment with NUCALA. The magnitude of reduction in the indicated populations described below were observed within 4 weeks of treatment and were maintained throughout the treatment period.</p><p>In patients with severe asthma (adults/adolescents) or COPD (adults), following a dose of 100&nbsp;mg administered subcutaneously every 4 weeks for 32 and 52 weeks respectively, the blood eosinophils were reduced to a geometric mean count of 40&nbsp;cells/&micro;L. This corresponds to a geometric mean reduction of 84% and 79%compared to placebo, respectively. This magnitude of blood eosinophils reduction was maintained in severe asthma patients (n=998) treated for a median of 2.8 years (range 4 weeks to 4.5 years) in open-label extension studies.</p><p>In children 6 to 11 years old with severe asthma, following either 40 mg (for a weight &lt;&nbsp;40kg) or 100&nbsp;mg (for a weight &ge; 40 kg) administered subcutaneously every 4 weeks for 52 weeks, the blood eosinophils were reduced to a geometric mean count of 48 and 44&nbsp;cells/&micro;L, respectively with a reduction from baseline of 85% and 87%, respectively.</p><p>In patients with EGPA following a dose of 300&nbsp;mg administered subcutaneously every 4 weeks for 52 weeks, blood eosinophils were reduced to a geometric mean count of 38&nbsp;cells/&micro;L. There was a geometric mean reduction of 83% compared to placebo.</p><p><strong>Immunogenicity</strong></p><p>Consistent with the potentially immunogenic properties of protein and peptide therapeutics, patients may develop antibodies to mepolizumab following treatment. In subjects with severe asthma, COPD and EGPA who received at least one dose of 100&nbsp;mg, 100&nbsp;mg and 300&nbsp;mg respectively, administered subcutaneously every four weeks, 15/260 (6%), 27/615 (4%) and 1/68 (1%) had detectable anti-mepolizumab antibodies. The immunogenicity profile of mepolizumab in severe asthma patients (n=998) treated for a median of 2.8 years (range 4 weeks to 4.5 years) in open-label extension studies was similar to that observed in the placebo-controlled studies. In children 6 to 11 years with severe asthma following either 40&nbsp;mg SC (for a weight &lt;&nbsp;40kg) or 100 mg SC (for a weight &ge; 40&nbsp;kg), 2/35 (6%) had detectable anti-mepolizumab antibodies during the initial short phase of the study. No children had detectable anti-mepolizumab antibodies during the long-term phase of the study. Neutralising antibodies were detected in one adult subject with severe asthma. Anti-mepolizumab antibodies did not discernibly impact the PK or PD of mepolizumab treatment in the majority of patients and there was no evidence of a correlation between antibody titres and change in eosinophil level.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following subcutaneous dosing in subjects with moderate/severe asthma, mepolizumab exhibited approximately dose-proportional pharmacokinetics over a dose range of 12.5 mg to 250 mg. Mepolizumab pharmacokinetics were consistent in subjects with asthma, COPD or EGPA. The exposure at 300&nbsp;mg in subjects with EGPA was approximately three times that observed at 100&nbsp;mg in subjects with severe asthma or COPD. In a PK comparability study conducted in healthy subjects, following administration of a single 100&nbsp;mg subcutaneous dose, mepolizumab pharmacokinetics were comparable between formulations.</p><p>&nbsp;</p><p>Absorption</p><p style="margin-right:-.1pt">Following subcutaneous administration to healthy subjects or patients with asthma, mepolizumab was absorbed slowly with a median time to reach maximum plasma concentration (T<sub>max</sub>) ranging from 4 to 8 days.</p><p style="margin-right:-.1pt">Following a single subcutaneous administration in the abdomen, thigh or arm of healthy subjects, mepolizumab absolute bioavailability was 64%, 71% and 75%, respectively. In patients with asthma the absolute bioavailability of mepolizumab administered subcutaneously in the arm ranged from 74-80%.&nbsp; Following repeat subcutaneous administration every 4 weeks, there is approximately a two-fold accumulation at steady state.</p><p>Distribution</p><p style="margin-right:-.1pt">Following a single intravenous administration of mepolizumab to patients with asthma, the mean volume of distribution is 55 to 85&nbsp;mL/kg.</p><p>Metabolism</p><p>Mepolizumab is a humanised IgG1 monoclonal antibody degraded by proteolytic enzymes which are widely distributed in the body and not restricted to hepatic tissue.</p><p>Elimination</p><p>Following a single intravenous administration to patients with asthma, the mean systemic clearance (CL) ranged from 1.9 to 3.3&nbsp;mL/day/kg, with a mean terminal half-life of approximately 20 days.&nbsp; Following subcutaneous administration of mepolizumab the mean terminal half-life (t1/2) ranged from 16 to 22 days. In the population pharmacokinetic analysis estimated mepolizumab systemic clearance was 3.1&nbsp;mL/day/kg.</p><p>&nbsp;</p><p>Special Patient Populations</p><p>The population pharmacokinetics of mepolizumab were analysed to evaluate the effects of demographic characteristics. Analyses of these limited data suggest that no dose adjustments are necessary for race or gender.</p><p><strong>Children</strong></p><p>Mepolizumab pharmacokinetics following subcutaneous administration in subjects 6 to 11 years old with severe asthma were broadly consistent with adults and adolescents after accounting for bodyweight and bioavailability. The absolute subcutaneous bioavailability appears complete compared to that observed in adults and adolescents of 76%. Exposure following subcutaneous administration of either 40&nbsp;mg (for a weight &lt;&nbsp;40kg) or 100&nbsp;mg (for a weight &ge; 40&nbsp;kg) was 1.32 and 1.97 times of that observed in adults at 100&nbsp;mg .</p><p>Investigation of a 40&nbsp;mg subcutaneous dosing regimen administered every 4 weeks in children 6 to 11 years old over a 15-70&nbsp;kg broad weight range by PK modelling and simulation predicts that the exposure of this dosing regimen would remain on average within 38% of adults at 100&nbsp;mg. This dosing regimen is considered acceptable due to the wide therapeutic index of mepolizumab.</p><p>Mepolizumab pharmacokinetics in children (6 to 17 years) with EGPA were predicted using modelling and simulation, based on pharmacokinetics in other eosinophilic diseases, and are expected to be consistent with those observed in children with severe asthma.</p><p><strong>Elderly patients </strong><strong>(&gt; 65&nbsp;years old)</strong></p><p>No formal studies have been conducted in elderly patients. However, in the population pharmacokinetic analysis, there was no indication of an effect of age (12- 82 years of age) on the pharmacokinetics of mepolizumab.</p><p><strong>Renal impairment</strong></p><p>No formal studies have been conducted to investigate the effect of renal impairment on the pharmacokinetics of mepolizumab. Based on population pharmacokinetic analyses, no dose adjustment is required in patients with creatinine clearance values between 50‑80&nbsp;mL/min. There are limited data available in patients with creatinine clearance values &lt;50&nbsp;mL/min.</p><p><strong>Hepatic impairment</strong></p><p>No formal studies have been conducted to investigate the effect of hepatic impairment on the pharmacokinetics of mepolizumab.&nbsp; Since mepolizumab is degraded by widely distributed proteolytic enzymes, not restricted to hepatic tissue, changes in hepatic function are unlikely to have any effect on the elimination of mepolizumab.</p><p>Clinical Studies</p><p><strong><u>Severe asthma</u></strong></p><p>The efficacy of <em>NUCALA</em> in the treatment of a targeted group of subjects with severe eosinophilic asthma was evaluated in 3 randomised, double-blind, parallel-group clinical studies of between 24-52 weeks duration, in patients aged 12 years and older. These studies were designed to evaluate the efficacy of <em>NUCALA</em> administered once every 4 weeks by subcutaneous or intravenous injection in severe eosinophilic asthma patients not controlled on their standard of care [e.g., inhaled corticosteroids (ICS), oral corticosteroids (OCS), combination ICS and long-acting beta<sub>2</sub>-adrenergic agonists (LABA), leukotriene modifiers, short-acting beta<sub>2</sub>-adrenergic agonists (SABA)].</p><p><u>Placebo Controlled Studies</u></p><p>In MEA112997, a randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of 52 weeks duration in 616 patients, results demonstrated that mepolizumab (75&nbsp;mg, 250&nbsp;mg or 750&nbsp;mg) significantly reduced asthma exacerbations when administered intravenously compared to placebo. There was no statistically significant difference in effect seen between the 3 studied doses. Blood eosinophil counts greater than or equal to 150&nbsp;cells/&micro;l at screening; or blood eosinophils &ge;300&nbsp;cells/&micro;l in the past 12 months predicted subjects who would benefit most from <em>NUCALA</em> therapy. Results from this study were used to determine dose selection for the studies using subcutaneous mepolizumab administration.&nbsp; <em>NUCALA</em> is not indicated for intravenous use, and should only be administered by the subcutaneous route.<strong><s> </s></strong></p><p>&nbsp;</p><p><u>Exacerbation Reduction (MEA115588)</u></p><p>MEA115588 was a randomised, double-blind, placebo-controlled, parallel-group, multi-centre<s> </s>study which<em> </em>evaluated the efficacy and safety of mepolizumab as add-on therapy in 576 patients with severe eosinophilic asthma. This study evaluated the frequency of clinically significant exacerbations of asthma, defined as: worsening of asthma requiring use of oral/systemic corticosteroids and/or hospitalisation and/or emergency department visits.</p><p>Patients were aged 12 years of age or older, with a history of two or more asthma exacerbations in the past 12 months and not controlled on their current asthma drug therapies [i.e., high-dose inhaled corticosteroids (ICS) in combination with at least another controller such as long-acting beta<sub>2</sub>-adrenergic agonists (LABA) or leukotriene modifiers]. Patients were allowed to be on oral corticosteroid therapy and continued to receive their existing asthma medication during the study. Severe eosinophilic asthma patients were identified by peripheral blood eosinophils greater than or equal to 150&nbsp;cells/&mu;l within 6 weeks of randomisation (first dose) or blood eosinophils greater than or equal to 300&nbsp;cells/&mu;l within the past 12 months of randomisation.</p><p>&nbsp;</p><p>Patients received either <em>NUCALA</em> 100&nbsp;mg administered subcutaneously (SC), mepolizumab 75&nbsp;mg administered intravenously (IV), or placebo treatment once every 4 weeks over 32 weeks.</p><p>The primary endpoint, reduction in the frequency of clinically significant exacerbations of asthma was statistically significant (p&lt;0.001). Table 1, provides the results of the primary endpoint<strong><em> </em></strong>and secondary endpoints of MEA115588.</p><p><strong>&nbsp;</strong></p><p><strong>Table 1: Results of primary and secondary endpoints at Week 32 in the Intent to Treat population (MEA115588)</strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-right:.3in; text-align:right">&nbsp;</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center"><em>NUCALA</em></p><p style="margin-left:0in; margin-right:21.55pt; text-align:center">(100&nbsp;mg SC)</p><p style="margin-left:0in; margin-right:21.55pt; text-align:center">N= 194</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">Placebo</p><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;</p><p style="margin-left:0in; margin-right:21.55pt; text-align:center">N= 191</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:375.65pt"><p style="margin-left:0in; margin-right:0in"><strong>Primary endpoint</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top; width:375.65pt"><p style="margin-left:0in; margin-right:21.55pt"><strong>Frequency of Clinically Significant Exacerbations</strong></p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">Exacerbation rate per year</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">0.83</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">1.74</p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">Percent reduction</p><p style="margin-left:0in; margin-right:21.55pt">Rate ratio (95% CI)</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">53%</p><p style="margin-left:0in; margin-right:21.55pt; text-align:center">0.47 (0.35, 0.64)</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">-</p><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">p-value</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&lt;0.001</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:375.65pt"><p style="margin-left:0in; margin-right:0in"><strong>Secondary endpoints</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top; width:375.65pt"><p style="margin-left:0in; margin-right:21.55pt"><strong>Frequency of Exacerbations requiring hospitalisations/emergency room visits</strong></p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">Exacerbation rate per year</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">0.08</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">0.20</p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">Percent reduction</p><p style="margin-left:0in; margin-right:21.55pt">Rate ratio (95% CI)</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">61%</p><p style="margin-left:0in; margin-right:21.55pt; text-align:center">0.39 (0.18, 0.83)</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">_</p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">p-value</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">0.015</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:375.65pt"><p style="margin-left:0in; margin-right:21.55pt"><strong>Frequency of Exacerbations requiring hospitalisation</strong></p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">Exacerbations rate per year</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">0.03</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">0.10</p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">Percent reduction</p><p style="margin-left:0in; margin-right:21.55pt">Rate ratio (95% CI)</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;69%</p><p style="margin-left:0in; margin-right:21.55pt; text-align:center">0.31 (0.11, 0.91)</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">_</p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">p-value</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">0.034</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:375.65pt"><p style="margin-left:0in; margin-right:21.55pt"><strong>Pre-bronchodilator FEV<sub>1</sub> (mL)<em> </em>at Week 32</strong></p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">Mean Change from Baseline (SE)</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">183 (31.1)</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">86 (31.4)</p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">Difference (mepolizumab vs. placebo)</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">98</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">95% CI</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">11, 184</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">p-value</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">0.028</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:375.65pt"><p style="margin-left:0in; margin-right:21.55pt"><strong>St. George&rsquo;s Respiratory Questionnaire (SGRQ) at week 32</strong></p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">Mean Change From Baseline (SE)</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">-16.0 (1.13)</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:.3in; text-align:center">-9.0 (1.16)</p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">Difference (mepolizumab vs. placebo)</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:.3in; text-align:center">-7.0</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:.3in; text-align:center">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">95% CI</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:.3in; text-align:center">-10.2, -3.8</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:.3in; text-align:center">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:162.05pt"><p style="margin-left:0in; margin-right:21.55pt">p-value</p></td><td style="vertical-align:top; width:114.4pt"><p style="margin-left:0in; margin-right:.3in; text-align:center">&lt;0.001</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:.3in; text-align:center">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Oral Corticosteroid Reduction (MEA115575)</u></p><p>MEA115575 evaluated the effect of <em>NUCALA</em> 100&nbsp;mg SC on reducing the use of maintenance oral corticosteroids (OCS) while maintaining asthma control in subjects with severe eosinophilic asthma who were dependent on systemic corticosteroids. Patients had a peripheral blood eosinophil count of &sup3;300/mL in the 12 months prior screening or a peripheral blood eosinophil count of &sup3;150/mL at baseline. Patients were administered <em>NUCALA</em> or placebo treatment once every 4 weeks over the treatment period. The OCS dose was reduced every 4 weeks during the OCS reduction phase (Weeks 4-20), as long as asthma control was maintained. During the study patients continued their baseline asthma therapy [i.e., high-dose inhaled corticosteroids (ICS) in combination with at least another controller such as long-acting beta<sub>2</sub>-adrenergic agonists (LABA) or leukotriene modifiers].</p><p>This study enrolled a total of 135 patients: mean age of 50 years, 55% were female, 48% had been receiving oral steroid therapy for at least 5 years, and had a baseline mean prednisone equivalent dose of approximately 13&nbsp;mg per day.</p><p>The primary endpoint was the reduction in daily OCS dose (weeks 20-24) whilst maintaining asthma control compared with patients treated with placebo<strong><em> </em></strong>(see Table 2).</p><p><strong>Table 2: </strong><strong>Results of the primary and secondary endpoints</strong><strong> </strong><strong>in the Intent to Treat population (MEA115575).</strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-right:.3in; text-align:right">&nbsp;</p></td><td style="vertical-align:top; width:120.5pt"><p style="text-align:center"><em>NUCALA</em></p><p style="text-align:center">(100&nbsp;mg SC)</p><p style="text-align:center">N= 69</p></td><td style="vertical-align:top; width:99.2pt"><p style="text-align:center">Placebo</p><p style="text-align:center">&nbsp;</p><p style="text-align:center">N= 66</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:375.65pt"><p style="margin-left:0in; margin-right:21.55pt"><strong>Primary Endpoint</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top; width:375.65pt"><p style="margin-left:0in; margin-right:21.55pt"><strong>Percent Reduction in OCS from Baseline at Weeks 20-24 (%)</strong></p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-left:0in; margin-right:.3in">90% - 100%</p><p style="margin-left:0in; margin-right:.3in">75% - &lt;90%</p><p style="margin-left:0in; margin-right:.3in">50% - &lt;75%</p><p style="margin-left:0in; margin-right:.3in">&gt;0% - &lt;50%</p><p style="margin-left:0in; margin-right:21.55pt">No decrease in OCS/lack of asthma control/ withdrawal from treatment</p></td><td style="vertical-align:top; width:120.5pt"><p style="text-align:center">16 (23%)</p><p style="text-align:center">12 (17%)</p><p style="text-align:center">9 (13%)</p><p style="text-align:center">7 (10%)</p><p style="text-align:center">25 (36%)</p></td><td style="vertical-align:top; width:99.2pt"><p style="text-align:center">7(11%)</p><p style="text-align:center">5 (8%)</p><p style="text-align:center">10 (15%)</p><p style="text-align:center">7(11%)</p><p style="text-align:center">37 (56%)</p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-left:0in; margin-right:21.55pt">Odds ratio (95% CI)</p></td><td style="vertical-align:top; width:120.5pt"><p style="text-align:center">2.39 (1.25, 4.56)</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-left:0in; margin-right:21.55pt">p-value</p></td><td style="vertical-align:top; width:120.5pt"><p style="text-align:center">0.008</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:375.65pt"><p style="margin-left:0in; margin-right:21.55pt"><strong>Secondary Endpoints</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top; width:375.65pt"><p style="margin-left:0in; margin-right:21.55pt"><strong>Reduction in the daily OCS dose (%)</strong></p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-left:0in; margin-right:21.55pt">At least 50% reduction</p></td><td style="vertical-align:top; width:120.5pt"><p style="text-align:center">37 (54%)</p></td><td style="vertical-align:top; width:99.2pt"><p style="text-align:center">22 (33%)</p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-left:0in; margin-right:21.55pt">Odds ratio (95% CI)</p></td><td style="vertical-align:top; width:120.5pt"><p style="text-align:center">2.26 (1.10, 4.65)</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-left:0in; margin-right:21.55pt">p-value</p></td><td style="vertical-align:top; width:120.5pt"><p style="text-align:center">0.027</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:375.65pt"><p style="margin-left:0in; margin-right:21.55pt"><strong>Reduction in the daily OCS dose (%)</strong></p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-left:0in; margin-right:21.55pt">To &le;5mg/day</p></td><td style="vertical-align:top; width:120.5pt"><p style="text-align:center">37 (54%)</p></td><td style="vertical-align:top; width:99.2pt"><p style="text-align:center">21 (32%)</p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-left:0in; margin-right:21.55pt">Odds ratio (95% CI)</p></td><td style="vertical-align:top; width:120.5pt"><p style="text-align:center">2.45 (1.12, 5.37)</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-left:0in; margin-right:21.55pt">p-value</p></td><td style="vertical-align:top; width:120.5pt"><p style="text-align:center">0.025</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:375.65pt"><p style="margin-left:0in; margin-right:21.55pt"><strong>Reduction in the daily OCS dose</strong></p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-left:0in; margin-right:21.55pt">To 0&nbsp;mg/Day</p></td><td style="vertical-align:top; width:120.5pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">10 (14%)</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center"><em>5 (8%)</em></p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-left:0in; margin-right:21.55pt">Odds ratio (95% CI)</p></td><td style="vertical-align:top; width:120.5pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">1.67 (0.49, 5.75)</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center"><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-left:0in; margin-right:21.55pt">p-value</p></td><td style="vertical-align:top; width:120.5pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center">0.414</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:0in; margin-right:21.55pt; text-align:center"><em>&nbsp;</em></p></td></tr><tr><td colspan="3" style="vertical-align:top; width:375.65pt"><p style="margin-left:0in; margin-right:21.55pt"><strong>Median Percentage Reduction in Daily OCS Dose </strong></p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-right:21.55pt">Median % reduction from baseline (95% CI)</p></td><td style="vertical-align:top; width:120.5pt"><p style="margin-right:21.55pt; text-align:center">50.0 (20.0, 75.0)</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-right:21.55pt; text-align:center">0.0 (-20.0, 33.3)</p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-right:21.55pt">Median difference (95% CI)</p></td><td style="vertical-align:top; width:120.5pt"><p style="margin-right:21.55pt; text-align:center">-30.0 (-66.7, 0.0)</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:155.95pt"><p style="margin-right:21.55pt">p-value</p></td><td style="vertical-align:top; width:120.5pt"><p style="margin-right:21.55pt; text-align:center">0.007</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-right:21.55pt; text-align:center">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Additionally, health-related quality of life was measured using SGRQ. At Week 24, there was a statistically significant improvement in the mean SGRQ score for <em>NUCALA</em> compared with placebo: -5.8 (95% CI: -10.6,-1.0; P=0.019). At Week 24, the proportion of subjects with a clinically meaningful decrease in SGRQ score (defined as a decrease of at least 4 units from baseline) was greater for <em>NUCALA</em> (58%, 40/69) compared with placebo (41%, 27/66).</p><p>The long-term efficacy profile of NUCALA in severe asthma patients (n=998) treated for a median of 2.8 years (range 4 weeks to 4.5 years) in open-label extension studies MEA115666, MEA115661 and 201312 was generally consistent with the 3 placebo-controlled studies.</p><p><u>Eosinophilic Granulomatosis with Polyangiitis (EGPA)</u></p><p>MEA115921 was a randomised, double-blind, placebo-controlled, 52 week study which evaluated 136 patients &ge; 18 years old with relapsing or refractory EGPA and who were on stable oral corticosteroid therapy (OCS; &ge;7.5 to &pound;50 mg /day prednisolone/prednisone). Fifty-three percent (n=72) were also on concomitant stable immunosuppressant therapy.</p><p>Patients received a 300&nbsp;mg dose of NUCALA or placebo administered subcutaneously once every 4&nbsp;weeks in addition to their background prednisolone/prednisone with or without immunosuppressive therapy. The OCS dose was tapered at the discretion of the investigator.</p><p>The co- primary endpoints were the total accrued duration of remission, defined as a Birmingham Vasculitis Activity Score (BVAS)=0 (no active vasculitis) plus prednisolone/prednisone dose &le;4 mg/day, and the proportion of subjects in remission at both 36 and 48 weeks of treatment.&nbsp;</p><p><u>Remission</u></p><p>Compared with placebo, subjects receiving NUCALA 300&nbsp;mg achieved a significantly greater accrued time in remission. Additionally, compared to placebo, a significantly higher proportion of subjects receiving NUCALA 300&nbsp;mg achieved remission at both Week 36 and Week 48 (Table 3).</p><p>&nbsp;</p><p>Table 3:&nbsp; Analyses of Co-Primary Endpoints (ITT Population)</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1" style="width:100.0%"><tbody><tr><td style="vertical-align:top; width:57.4%"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:42.32%"><p>Number (%) of Subjects</p></td></tr><tr><td style="vertical-align:top; width:57.4%"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top; width:18.82%"><p>Placebo</p><p>N=68</p></td><td style="vertical-align:top; width:23.5%"><p>NUCALA 300&nbsp;mg</p><p>N=68</p></td></tr></tbody></table><table cellspacing="0" cellpadding="0" border="1" style="width:100.0%"><tbody><tr><td style="vertical-align:top; width:57.34%"><p>Accrued Duration of Remission Over 52 Weeks</p></td><td style="vertical-align:top; width:18.8%"><p>&nbsp;</p></td><td style="vertical-align:top; width:23.5%"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:57.34%"><p>0 weeks</p></td><td style="vertical-align:top; width:18.8%"><p>55 (81)</p></td><td style="vertical-align:top; width:23.5%"><p>32 (47)</p></td></tr><tr><td style="vertical-align:top; width:57.34%"><p>&gt;0 to &lt;12 weeks</p></td><td style="vertical-align:top; width:18.8%"><p>&nbsp; 8 (12)</p></td><td style="vertical-align:top; width:23.5%"><p>&nbsp; 8 (12)</p></td></tr><tr><td style="vertical-align:top; width:57.34%"><p>12 to &lt;24 weeks</p></td><td style="vertical-align:top; width:18.8%"><p>3 (4)</p></td><td style="vertical-align:top; width:23.5%"><p>&nbsp; 9 (13)</p></td></tr><tr><td style="vertical-align:top; width:57.34%"><p>24 to &lt;36 weeks</p></td><td style="vertical-align:top; width:18.8%"><p>0</p></td><td style="vertical-align:top; width:23.5%"><p>10 (15)</p></td></tr><tr><td style="vertical-align:top; width:57.34%"><p>&sup3;36 weeks</p></td><td style="vertical-align:top; width:18.8%"><p>2 (3)</p></td><td style="vertical-align:top; width:23.5%"><p>&nbsp; 9 (13)</p></td></tr></tbody></table><table cellspacing="0" cellpadding="0" border="1" style="width:100.0%"><tbody><tr><td style="vertical-align:top; width:57.34%"><p>Odds ratio (NUCALA/placebo)</p></td><td style="vertical-align:top; width:18.8%"><p>&nbsp;</p></td><td style="vertical-align:top; width:23.5%"><p>5.91</p></td></tr><tr><td style="vertical-align:top; width:57.34%"><p>95% CI</p></td><td style="vertical-align:top; width:18.8%"><p>---</p></td><td style="vertical-align:top; width:23.5%"><p>2.68, 13.03</p></td></tr><tr><td style="vertical-align:top; width:57.34%"><p>p-value</p></td><td style="vertical-align:top; width:18.8%"><p>---</p></td><td style="vertical-align:top; width:23.5%"><p>&lt;0.001</p></td></tr></tbody></table><table cellspacing="0" cellpadding="0" border="1" style="width:100.0%"><tbody><tr><td style="vertical-align:top; width:57.44%"><p>&nbsp;Subjects in Remission at Weeks 36 and 48</p></td><td style="vertical-align:top; width:18.8%"><p>2 (3)</p></td><td style="vertical-align:top; width:23.64%"><p>22 (32)</p></td></tr></tbody></table><table cellspacing="0" cellpadding="0" border="1" style="width:100.0%"><tbody><tr><td style="vertical-align:top; width:57.44%"><p>Odds ratio (NUCALA/placebo)</p></td><td style="vertical-align:top; width:18.8%"><p>&nbsp;</p></td><td style="vertical-align:top; width:23.64%"><p>16.74</p></td></tr><tr><td style="vertical-align:top; width:57.44%"><p>95% CI</p></td><td style="vertical-align:top; width:18.8%"><p>---</p></td><td style="vertical-align:top; width:23.64%"><p>3.61, 77.56</p></td></tr><tr><td style="vertical-align:top; width:57.44%"><p>p-value</p></td><td style="vertical-align:top; width:18.8%"><p>---</p></td><td style="vertical-align:top; width:23.64%"><p>&lt;0.001</p></td></tr></tbody></table><p>An odds ratio &gt;1 favours NUCALA</p><p>Subjects receiving NUCALA 300&nbsp;mg achieved significantly greater accrued time in remission (p&lt;0.001), and a higher proportion of subjects receiving NUCALA 300&nbsp;mg were in remission at both Week 36 and Week 48 (p&lt;0.001), compared to placebo using the secondary endpoint remission definition of BVAS=0 plus prednisolone/prednisone &le;7.5&nbsp;mg/day.</p><p><u>Relapse</u></p><p>Compared with placebo, the time to first relapse (defined as worsening related to vasculitis, asthma, or sino-nasal symptoms requiring an increase in dose of corticosteroids or immunosuppressive therapy or hospitalisation), was significantly longer for subjects receiving NUCALA 300&nbsp;mg (p&lt;0.001) Additionally, subjects receiving NUCALA had a 50% reduction in annualised relapse rate compared with placebo: 1.14 vs 2.27, respectively.</p><p><u>Oral Corticosteroid Reduction</u></p><p>Compared with placebo, subjects receiving NUCALA 300&nbsp;mg had a lower average daily oral corticosteroid dose during Weeks 48 to 52 (p &lt;0.001). In the NUCALA 300&nbsp;mg group, 12&nbsp;subjects (18%) were able to taper completely off OCS therapy compared with 2&nbsp;subjects (3%) in the placebo group.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenesis/mutagenesis</p><p>As mepolizumab is a monoclonal antibody, no genotoxicity or carcinogenicity studies have been conducted.</p><p>Reproductive Toxicology</p><p><strong>Fertility</strong></p><p>No impairment of fertility was observed in a fertility and general reproduction toxicity study in mice performed with an analogous antibody that inhibits IL-5 in mice. This study did not include a littering or functional F1 assessment.</p><p><strong>Pregnancy</strong></p><p>In monkeys, mepolizumab had no effect on pregnancy or on embryonic/foetal and postnatal development (including immune function) of the offspring. Examinations for internal or skeletal malformations were not performed. Data in cynomolgus monkeys demonstrate that mepolizumab crosses the placenta. Concentrations of mepolizumab were approximately 2.4&nbsp;times higher in infants than in mothers for several months post partum and did not affect the immune system of the infants.</p><p>Animal toxicology and pharmacology</p><p>Non-clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology or repeated dose toxicity studies in monkeys. Intravenous and subcutaneous administration to monkeys was associated with reductions in peripheral and lung eosinophil counts, with no toxicological findings.</p><p>Eosinophils have been associated with immune system responses to some parasitic infections.&nbsp; Studies conducted in mice treated with anti-IL-5 antibodies or genetically deficient in IL-5 or eosinophils have not shown impaired ability to clear parasitic infections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sucrose</p><p>Sodium phosphate dibasic heptahydrate</p><p>Polysorbate 80</p><p style="margin-left:28.35pt; text-indent:-28.35pt">Hydrochloric Acid</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not mix the reconstituted solution for injection with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Unopened Vial</u></strong></p><p>Store at between 2&deg;C and 8&deg;C.</p><p>Do not freeze.</p><p>Protect from light. Store in the original carton until use.</p><p><strong><u>Reconstituted solution</u></strong></p><p>After reconstitution with Water for Injection the product is stable for up to 8 hours when stored below 30&deg;C.</p><p>Do not freeze.</p><p>During administration, protection from light is not necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>NUCALA</em> is presented as a sterile lyophilised powder in a 10&nbsp;mL type I glass vial with bromobutyl rubber (non-latex) stopper and a gray aluminium overseal with a plastic flip-cap. The drug is supplied in a single use vial without a preservative.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>NUCALA</em> is provided as a lyophilised powder in a single-use vial for subcutaneous injection only. <em>NUCALA</em> does not contain a preservative therefore reconstitution by a healthcare professional should be carried out under aseptic conditions.</p><p style="text-align:justify">Once reconstituted, <em>NUCALA</em> will contain a concentration of 100&nbsp;mg/mL mepolizumab. The reconstituted solution of mepolizumab, if not used immediately, should be stored below 30&deg;C, and should not be frozen. Any unused concentrate or solution remaining after 8&nbsp;hours must be discarded</p><p><strong>Instructions for reconstitution of each vial</strong></p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Reconstitute the contents of the vial with <strong>1.2 mL of sterile Water for Injection</strong> preferably using a 2 to 3 mL syringe and a 21 gouge needle.&nbsp; The reconstituted solution will contain a concentration of 100&nbsp;mg/mL mepolizumab.</p><p style="margin-left:17.85pt; margin-right:0in; text-indent:-17.85pt"><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The stream of sterile Water for Injection should be directed vertically onto the centre of the lyophilised cake. Allow the vial to sit at room temperature during reconstitution, gently swirling the vial for 10 seconds with circular motion at 15 second intervals until the powder is dissolved.</p><p style="margin-left:17.85pt; margin-right:0in">&nbsp;</p><p style="margin-left:.25in"><em>Note: Do not shake the reconstituted solution during the procedure as this may lead to product foaming or precipitation. Reconstitution is typically complete within 5 minutes after the sterile water has been added, but it may take additional time. </em></p><p><!--[if !supportLists]-->3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If a mechanical reconstitution device (swirler) is used to reconstitute <em>NUCALA</em>, reconstitution can be accomplished by swirling at 450&nbsp;rpm for no longer than 10&nbsp;minutes. Alternatively, swirling at 1000&nbsp;rpm for no longer than 5&nbsp;minutes is acceptable.</p><p><!--[if !supportLists]-->4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Visually inspect the reconstituted solution for particulate matter and clarity prior to use.&nbsp; The solution should be clear to opalescent, and colourless to pale yellow or pale brown, free of visible particles. Small air bubbles, however, are expected and acceptable. If particulate matter remains in the solution or if the solution appears cloudy or milky, the solution must not be used.</p><p><!--[if !supportLists]-->5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The reconstituted solution of <em>NUCALA</em>, if not used immediately:</p><p style="margin-left:35.7pt; margin-right:0in; text-indent:-17.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Store below 30&deg;C</p><p style="margin-left:35.7pt; margin-right:0in; text-indent:-17.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Discard if not used within 8 hours of reconstitution</p><p style="margin-left:35.7pt; margin-right:0in; text-indent:-17.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not mix with other medications</p><p style="margin-left:35.7pt; margin-right:0in; text-indent:-17.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not freeze</p><p>&nbsp;</p><p><strong>Instructions for administration of each 100 mg dose</strong></p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->For subcutaneous administration a 1 mL polypropylene syringe fitted with a disposable needle 21 gauge to 27 gauge x 0.5 inch (13 mm) should preferably be used.</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Just prior to administration, remove 1&nbsp;mL of reconstituted <em>NUCALA.</em>&nbsp; <strong>Do </strong><strong>not shake</strong> the reconstituted solution during the procedure as this could lead to product foaming or precipitation.</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Administer the 1&nbsp;mL injection (equivalent to 100&nbsp;mg mepolizumab) subcutaneously into the upper arm, thigh, or abdomen.</p><p>If more than one vial is required for administration of the prescribed dosage, repeat steps 1 to 3. It is recommended that individual injection sites are separated by at least 5 cm.</p><p>&nbsp;</p><p>Not all presentations are available in every country.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
GlaxoSmithKline Manufacturing S.p.A*, Parma, Italy
Marketing Authorisation Holder:
Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia. 
*member of the GlaxoSmithKline group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number:  GDS12/IPI12
Date of issue: 25 June 2019
NUCALA is a trademark owned by or licensed to the GSK group of companies.

©2019 GSK group of companies. All rights reserved.

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>